Articles
15 February 1997

Effect of Cytomegalovirus Infection Status on First-Year Mortality Rates among Orthotopic Liver Transplant Recipients

Publication: Annals of Internal Medicine
Volume 126, Number 4

Abstract

Background:

To reduce the mortality rate associated with liver transplantation, it is important to identify the risk factors for increased mortality among liver transplant recipients. It has been suggested that cytomegalovirus (CMV) infection is one such risk factor, but no studies have examined mortality rates associated with the CMV serologic status of the donor and recipient by using multivariate techniques.

Objective:

To study the effect of CMV on 1-year mortality rates in orthotopic liver transplant recipients.

Design:

Intention-to-treat analysis of a cohort.

Patients:

146 liver transplant recipients who were enrolled in a multicenter, randomized, placebo-controlled, intervention trial.

Setting:

Four university-affiliated transplantation centers.

Results:

1-year mortality rates for the four strata of donor and recipient CMV serologic status before transplantation were as follows: seronegative donor and recipient, 11%; seronegative donor and seropositive recipient, 22%; seropositive donor and recipient, 30%; and seropositive donor and seronegative recipient, 44% (P = 0.0091). Multivariate analysis using a time-dependent Cox proportional-hazards model showed that retransplantation (relative risk, 4.6 [95% CI, 1.9 to 10.7]; P < 0.001); total number of units of blood products administered during transplantation (relative risk, 1.006 per unit [CI, 1.003 to 1.010]; P < 0.001); and presence of CMV disease (relative risk, 3.9 [CI, 1.8 to 8.5]; P < 0.001), invasive fungal disease (relative risk, 3.3 [CI, 1.5 to 7.1]; P = 0.0020), and bacteremia (relative risk, 2.5 [CI, 1.2 to 5.2]; P = 0.0136) were independently associated with higher mortality rates. If post-transplantation variables that were highly correlated with donor and recipient CMV serologic status were restricted from the model, donor and recipient CMV serologic status was the only pretransplantation variable independently associated with higher mortality rates (P = 0.002).

Conclusion:

Donor and recipient CMV serologic status is a significant pretransplantation determinant for death in liver transplant recipients.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Wiesner RH, Marin E, Porayko MK, Steers JL, Krom RA, Paya CV. Advances in the diagnosis, treatment, and prevention of cytomegalovirus infections after liver transplantation. Gastroenterol Clin North Am. 1993; 22:351-66.
2.
Todo S, Fung JJ, Starzl TE, Tzakis A, Doyle H, Abu-Elmagd K, et al. Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression. Ann Surg. 1994; 220:297-309.
3.
Delmonico FL, Jenkins RL, Freeman R, Vacanti J, Bradley J, Dienstag JL, et al. The high-risk liver allograft recipient. Should allocation policy consider outcome? Arch Surg. 1992; 127:579-84.
4.
Adler M, Gavaler JS, Duquesnoy R, Fung JJ, Svanas G, Starzl TE, et al. Relationship between the diagnosis, preoperative evaluation, and prognosis after orthotopic liver transplantation. Ann Surg. 1988; 208:196-202.
5.
Motschman TL, Taswell HF, Brecher ME, Rakela J, Grambsch PM, Larson-Keller JJ, et al. Intraoperative blood loss and patient and graft survival in orthotopic liver transplantation: their relationship to clinical and laboratory data. Mayo Clin Proc. 1989; 64:346-55.
6.
Baliga P, Merion RM, Turcotte JG, Ham JM, Henley KS, Lucey MR, et al. Preoperative risk factor assessment in liver transplantation. Surgery. 1992; 112:704-11.
7.
Cuervas-Mons V, Millan I, Gavaler JS, Starzl TE, Van Thiel DH. Prognostic value of preoperatively obtained clinical and laboratory data in predicting survival following orthotopic liver transplantation. Hepatology. 1986; 6:922-7.
8.
Gonwa TA, Klintmalm GB, Levy M, Jennings LS, Goldstein RM, Husberg BS. Impact of pretransplant renal function on survival after liver transplantation. Transplantation. 1995; 59:361-5.
9.
Pikul J, Sharpe MD, Lowndes R, Ghent CN. Degree of preoperative malnutrition is predictive of postoperative morbidity and mortality in liver transplant recipients. Transplantation. 1994; 57:469-72.
10.
Stratta RJ, Shaeffer MS, Markin RS, Wood RP, Langnas AN, Reed EC, et al. Cytomegalovirus infection and disease after liver transplantation. An overview. Dig Dis Sci. 1992; 37:673-88.
11.
Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA. 1989; 261:3561-6.
12.
Ettinger NA, Balley TC, Trulock EP, Storch GA, Anderson D, Raab S, et al. Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Washington University Lung Transplant Group. Am Rev Respir Dis. 1993; 147:1017-23.
13.
Snydman DR, Werner BG, Dougherty NN, Griffith J, Rubin RH, Dienstag JL, et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. The Boston Center for Liver Transplantation CMVIG Study Group. Ann Intern Med. 1993; 119:984-91.
14.
Falagas ME, Snydman DR, Griffith J, Werner BG. Exposure to cytomegalovirus from the donated organ is a risk factor for bacteremia in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. Clin Infect Dis. 1996; 23:468-74.
15.
SAS/STAT User's Guide. Version 6, 4th edition. Cary, NC: SAS Institute, Inc.; 1990.
16.
Markus BH, Duquesnoy RJ, Gordon RD, Fung JJ, Vanek M, Klintmalm G, et al. Histocompatibility and liver transplant outcome. Does HLA exert a dualistic effect? Transplantation. 1988; 46:372-7.
17.
Winston DJ, Wirin D, Shaked A, Busuttil RW. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet. 1995; 345:69-74.
18.
Patel R, Snydman DR, Rubin RH, Ho M, Pescovitz M, Martin M, et al. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation. 1996; 61:1279-89.
19.
Collins LA, Samore MH, Roberts MS, Luzzati R, Jenkins RL, Lewis WD, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis. 1994; 170:644-52.

Information & Authors

Information

Published In

cover image Annals of Internal Medicine
Annals of Internal Medicine
Volume 126Number 415 February 1997
Pages: 275 - 279

History

Published in issue: 15 February 1997
Published online: 15 August 2000

Keywords

Authors

Affiliations

Matthew E. Falagas, MD, MSc
The Boston Center for Liver Transplantation CMVIG Study Group*.
From the New England Medical Center and the Massachusetts State Laboratory Institute, Boston, Massachusetts.
*For members of the Boston Center for Liver Transplantation CMVIG Study Group, see the Appendix.
David R. Snydman, MD
The Boston Center for Liver Transplantation CMVIG Study Group*.
From the New England Medical Center and the Massachusetts State Laboratory Institute, Boston, Massachusetts.
*For members of the Boston Center for Liver Transplantation CMVIG Study Group, see the Appendix.
John Griffith, PhD
The Boston Center for Liver Transplantation CMVIG Study Group*.
From the New England Medical Center and the Massachusetts State Laboratory Institute, Boston, Massachusetts.
*For members of the Boston Center for Liver Transplantation CMVIG Study Group, see the Appendix.
Robin Ruthazer, MPH
The Boston Center for Liver Transplantation CMVIG Study Group*.
From the New England Medical Center and the Massachusetts State Laboratory Institute, Boston, Massachusetts.
*For members of the Boston Center for Liver Transplantation CMVIG Study Group, see the Appendix.
Barbara G. Werner, PhD
The Boston Center for Liver Transplantation CMVIG Study Group*.
From the New England Medical Center and the Massachusetts State Laboratory Institute, Boston, Massachusetts.
*For members of the Boston Center for Liver Transplantation CMVIG Study Group, see the Appendix.
Acknowledgment: The authors thank Roselia Martinez for preparation of the manuscript.
Grant Support: In part by grant R10 DK31389 from the National Institutes of Health and a grant from MedImmune, Inc. (Gaithersburg, Maryland).
Corresponding Author: David R. Snydman, MD, New England Medical Center, Box 238, 750 Washington Street, Boston, MA 02111.
Current Author Addresses: Drs. Falagas, Snydman, and Griffith and Ms. Ruthazer: New England Medical Center, 750 Washington Street, Boston, MA 02111.

Metrics & Citations

Metrics

Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format





Download article citation data for:
Matthew E. Falagas, David R. Snydman, John Griffith, et al. Effect of Cytomegalovirus Infection Status on First-Year Mortality Rates among Orthotopic Liver Transplant Recipients. Ann Intern Med.1997;126:275-279. doi:10.7326/0003-4819-126-4-199702150-00003

View More

Get Access

Login Options:
Purchase

You will be redirected to acponline.org to sign-in to Annals to complete your purchase.

Create your Free Account

You will be redirected to acponline.org to create an account that will provide access to Annals.

View options

PDF/ePub

View PDF/ePub

Related in ACP Journals

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media